Minimal Residual Disease negativity as a goal of therapy for multiple myeloma: an interview with Rafael Alonso
Important information
The following feature is intended for healthcare professionals only. Please tick the box below to confirm that you are a healthcare professional.
Dr Rafael Alonso from the Department of Hematology at Hospital Universitario 12 de Octubre (CIBERONC CB16/12/00369, Madrid, Spain) discusses Minimal Residual Disease (MRD) negativity as a measure of depth of response in multiple myeloma. Dr Alonso also highlights how critical MRD negativity is for patients receiving frontline treatment, as well as his personal experience with MRD testing.
The opinions expressed in this video are of the contributor’s own and do not necessarily reflect the views of Oncology Central or Future Science Group.
Sponsored and funded by:
MAT-GLB-2300223 (1.0) 01/23